Developing allogeneic gamma delta T cell therapies for cancer
SIGMAR1 agonists for neurodegenerative and neurodevelopmental disorders
Modular vaccine platform based on immuno-material technology
Mining nature to discover new carbohydrates
Eradicating chronic disease-causing bacteria with customized phage therapies
Harnessing alternative splicing to restore health
Engineering macrophages and monocytes to attack cancer
First-in-class nanotherapeutics for neurodegenerative diseases
Topical therapeutics addressing the root cause of disease
Working to end the transplant shortage with Human Compatible xenotransplants
Developing one-time in vivo treatments to precisely engineer cells and cure diseases from within
Modulating the immune system with bacterial peptides
Discovering novel immunology through skin
Decoding the role of biomolecular condensates in driving disease
Human-first discovery of microbiome therapeutics
Cell-free production of RNA at metric-ton scale
Elegantly designed, selectively delivered and activated mRNA 2.0
Using 3-D cell culture to predict the best drug for every cancer patient
Restoring patient microbiomes to improve cancer survival
Searching the natural world for gene editing systems
Using microbial nucleic acid to diagnose early-stage cancer
Repairing neural circuits with transplanted, stem cell-derived neurons
Developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases
Getting gut bacteria back in balance through personalized diet and probiotics
Allogeneic, engineered cell therapies with broad applicability to multiple large indications
Industrializing drug discovery
Genome engineering technology leveraging mammal-derived enzymes and non-viral delivery
Harnessing the microbiome to treat and prevent inflammatory diseases
Developing antibodies that harness the body’s own regenerative pathways
Developing a pipeline of novel T cell therapies for cancer patients suffering from solid tumors
Curative gene therapies, regenerative, and precision medicines for rare heart diseases
Rationally designed microbial consortia to tune the body’s ecosystem
Genetically engineering healthy cells to enable selective cancer targeting
